Recipharm, Synthonics to promote novel drug delivery technology
Wednesday, May 8, 2013
Recipharm Pharmaceutical, a Swedish contract development and manufacturing organization (CDMO), and Synthonics, a specialty pharmaceutical company based in Blacksburg, Va., have formed a Joint Promotion Agreement.
Synthonics has developed a proprietary metal coordination chemistry that can significantly improve a compound’s delivery and absorption. The contract, the first of its kind to be entered into between the pair, will provide Recipharm customers full access to Synthonics’ metal coordination chemistry, improving the delivery and performance of their compounds. Recipharm provides services that assist pharmaceutical companies throughout Europe, the U.S., Japan and further afield with the development and formulation of products.
“We are pleased to partner with Synthonics to expand the services and solutions that we can offer our clients,” said Maria Lundberg, general manager of Recipharm. “The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products. Furthermore, our ability to offer such services through this novel partnership distinguishes us from other CDMOs.”
Ken Slepicka, CEO of Synthonics, said, “Synthonics is delighted to partner with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm’s formulation and development teams and believe that our chemistry will fit well in their existing tool kit of solutions. We expect this agreement to help us reach new clients and to expand the use of our chemistry.”